These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 18331435

  • 1. Anaemia in patients with chronic kidney disease: management with epoetin beta in primary care setting in New Zealand.
    Madhan KK, Chamberlain M, Anderson E.
    Nephrology (Carlton); 2008 Oct; 13(5):428-32. PubMed ID: 18331435
    [Abstract] [Full Text] [Related]

  • 2. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
    Wizemann V, Rutkowski B, Baldamus C, Scigalla P, Koytchev R, Epoetin Zeta Study Group.
    Curr Med Res Opin; 2008 Mar; 24(3):625-37. PubMed ID: 18208642
    [Abstract] [Full Text] [Related]

  • 3. Results of the European Survey on Anaemia Management 2003 (ESAM 2003): current status of anaemia management in dialysis patients, factors affecting epoetin dosage and changes in anaemia management over the last 5 years.
    Jacobs C, Frei D, Perkins AC.
    Nephrol Dial Transplant; 2005 May; 20 Suppl 3():iii3-24. PubMed ID: 15824128
    [Abstract] [Full Text] [Related]

  • 4. Epoetin delta is effective for the management of anaemia associated with chronic kidney disease.
    Spinowitz BS, Pratt RD, Epoetin Delta 2002 Study Group.
    Curr Med Res Opin; 2006 Dec; 22(12):2507-13. PubMed ID: 17166333
    [Abstract] [Full Text] [Related]

  • 5. Is early treatment of anaemia with epoetin-alpha beneficial to pre-dialysis chronic kidney disease patients? Results of a multicentre, open-label, prospective, randomized, comparative group trial.
    Macdougall IC, Temple RM, Kwan JT.
    Nephrol Dial Transplant; 2007 Mar; 22(3):784-93. PubMed ID: 16968726
    [Abstract] [Full Text] [Related]

  • 6. Prevalence and predictors of epoetin hyporesponsiveness in chronic kidney disease patients.
    Rossert J, Gassmann-Mayer C, Frei D, McClellan W.
    Nephrol Dial Transplant; 2007 Mar; 22(3):794-800. PubMed ID: 17210593
    [Abstract] [Full Text] [Related]

  • 7. Use of methoxy polyethylene glycol-epoetin beta in stage 3, 4 or 5 non-dialysis chronic kidney disease.
    Padullés-Zamora N, Comas-Sugrañes D, Pineda-Yuste Mdel M, Jódar-Masanés R, Martínez-Castelao A.
    Nefrologia; 2012 Mar; 32(2):221-7. PubMed ID: 22421952
    [Abstract] [Full Text] [Related]

  • 8. Epoetin responsiveness in peritoneal dialysis patients: a multi-center Slovenian study.
    Pajek J, Bucar-Pajek M, Grego K, Gucek A, Bevc S, Ekart R, Vujkovac B, Golob-Kosmina P, Kandus A, Bren AF.
    Ther Apher Dial; 2005 Jun; 9(3):228-32. PubMed ID: 15966995
    [Abstract] [Full Text] [Related]

  • 9. Administration of exogenous erythropoietin beta affects lipid peroxidation and serum paraoxonase-1 activity and concentration in predialysis patients with chronic renal disease and anaemia.
    Marsillach J, Martínez-Vea A, Marcas L, Mackness B, Mackness M, Ferré N, Joven J, Camps J.
    Clin Exp Pharmacol Physiol; 2007 Apr; 34(4):347-9. PubMed ID: 17324148
    [Abstract] [Full Text] [Related]

  • 10. Therapeutic effects of epoetin zeta in the treatment of chemotherapy-induced anaemia.
    Tzekova V, Mihaylov G, Elezovic I, Koytchev R, Epoetin Zeta Oncology Study Group.
    Curr Med Res Opin; 2009 Jul; 25(7):1689-97. PubMed ID: 19505200
    [Abstract] [Full Text] [Related]

  • 11. Epoetin delta, erythropoietin produced in a human cell line, in the management of anaemia in predialysis chronic kidney disease patients.
    Kwan JT, Pratt RD, Epoetin Delta Study Group.
    Curr Med Res Opin; 2007 Feb; 23(2):307-11. PubMed ID: 17288685
    [Abstract] [Full Text] [Related]

  • 12. Optimal treatment of renal anaemia (OPTA): improving the efficacy and efficiency of renal anaemia therapy in haemodialysis patients receiving intravenous epoetin.
    Hörl WH, Vanrenterghem Y, Canaud B, Mann J, Teatini U, Wanner C, Wikström B.
    Nephrol Dial Transplant; 2005 May; 20 Suppl 3():iii25-32. PubMed ID: 15824127
    [Abstract] [Full Text] [Related]

  • 13. [Anemia management in haemodialysis. EuCliD database in Spain].
    Avilés B, Coronel F, Pérez-García R, Marcelli D, Orlandini G, Ayala JA, Rentero R.
    Nefrologia; 2002 May; 22(6):555-63. PubMed ID: 12516289
    [Abstract] [Full Text] [Related]

  • 14. Once-weekly epoetin beta therapy in patients with solid tumours and chemotherapy-induced anaemia: a randomized, double-blind, dose-finding study.
    Heras P, Kritikos K, Hatzopoulos A, Mitsibounas D.
    Eur J Cancer Care (Engl); 2008 Nov; 17(6):619-23. PubMed ID: 18707619
    [Abstract] [Full Text] [Related]

  • 15. ORAMA: a study to investigate EBPG impact on renal anaemia - design and baseline data.
    Locatelli F, Covic A, Macdougall IC, Wiecek A, ORAMA Study Group.
    J Nephrol; 2008 Nov; 21(4):592-603. PubMed ID: 18651551
    [Abstract] [Full Text] [Related]

  • 16. Serum erythropoietin concentrations and responses to anaemia in patients with or without chronic kidney disease.
    Artunc F, Risler T.
    Nephrol Dial Transplant; 2007 Oct; 22(10):2900-8. PubMed ID: 17556407
    [Abstract] [Full Text] [Related]

  • 17. Epoetin Beta once-weekly therapy in anemic patients with solid tumors and non-myeloid hematological malignancies receiving chemotherapy.
    Spaëth D, Desablens B, Rodon P, Mennecier B, Oudard S, Moullet I, Ghomari K, Bergougnoux L, Bleuzen P, Jenabian A, Ifrah N.
    Oncology; 2008 Oct; 74(1-2):112-8. PubMed ID: 18547966
    [Abstract] [Full Text] [Related]

  • 18. r.hu-erythropoietin (EPO) treatment of pre-ESRD patients slows the rate of progression of renal decline.
    Tapolyai M, Kadomatsu S, Perera-Chong M.
    BMC Nephrol; 2003 Jun 17; 4():3. PubMed ID: 12809563
    [Abstract] [Full Text] [Related]

  • 19. [Iron deficiency is a common cause of bad response to epoetin treatment. It's important to follow iron status--not only the Hb value].
    Wallerstedt SM, Ljungman S, Broms E, Andrén L.
    Lakartidningen; 2003 Jun 17; 102(37):2550-1, 2553-5. PubMed ID: 16200900
    [Abstract] [Full Text] [Related]

  • 20. Cost-effectiveness analysis of treatment with epoietin-alpha for patients with anaemia due to renal failure: the case of Sweden.
    Glenngård AH, Persson U, Schön S.
    Scand J Urol Nephrol; 2008 Jun 17; 42(1):66-73. PubMed ID: 17907051
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.